TAI · 6446.TW
PharmaEssentia Corporation
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TWO · 6875.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 05:23 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Pharmosa Biopharm Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Pharmosa Biopharm Inc., a biotechnology firm based in Taiwan, specializes in the development of pharmaceutical products. Its current pipeline includes two key candidates: L606 and L608. L606 is an investigational inhalation/device combination therapy designed to treat both pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease. Similarly, L608 is another inhalation-based therapy, paired with a device, aimed at addressing pulmonary vascular disease. The company, which was established in 2000, originally operated under the name Pharmosa Limited before adopting its current name, Pharmosa Biopharm Inc., in October 2016. Its main offices are located in Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$39.05-NT$1.75 (-4.29%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$379.00-NT$13.00 (-3.32%)
Bora Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.78% below the high.
NT$167.50-NT$5.00 (-2.9%)
Lotus Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.67% below the high.
NT$419.00-NT$3.50 (-0.83%)
Pegavision Corp.’s quoted price sits in the upper half of its reported 52-week range, 4.12% below the high.
NT$26.95+NT$0.55 (+2.08%)
Intech Biopharm Corporation’s quoted price sits in the lower half of its reported 52-week range, 36.56% below the high.
NT$32.25-NT$0.90 (-2.71%)
Andros Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 29.82% below the high.
